Shares of Halyard Health Inc (NYSE:HYH) have been assigned an average rating of “Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $46.25.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Halyard Health from a “hold” rating to a “buy” rating and set a $53.00 price objective for the company in a report on Wednesday, December 6th. TheStreet upgraded shares of Halyard Health from a “c+” rating to a “b” rating in a report on Monday, December 4th. ValuEngine upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Stifel Nicolaus reiterated a “buy” rating and set a $52.00 price objective on shares of Halyard Health in a report on Friday, November 3rd. Finally, KeyCorp reiterated a “hold” rating on shares of Halyard Health in a report on Tuesday, October 17th.

A number of institutional investors and hedge funds have recently made changes to their positions in HYH. Riverhead Capital Management LLC lifted its holdings in Halyard Health by 88.1% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock valued at $126,000 after buying an additional 1,497 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Halyard Health by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 4,732 shares of the medical instruments supplier’s stock valued at $186,000 after purchasing an additional 711 shares in the last quarter. Jarislowsky Fraser Ltd bought a new stake in shares of Halyard Health in the 3rd quarter valued at about $200,000. Quotient Investors LLC bought a new stake in shares of Halyard Health in the 3rd quarter valued at about $203,000. Finally, QS Investors LLC raised its holdings in shares of Halyard Health by 305.6% in the 2nd quarter. QS Investors LLC now owns 5,176 shares of the medical instruments supplier’s stock valued at $203,000 after purchasing an additional 3,900 shares in the last quarter. Institutional investors own 90.31% of the company’s stock.

Halyard Health (HYH) traded up $0.69 during trading on Friday, hitting $47.59. 582,000 shares of the stock traded hands, compared to its average volume of 345,830. The company has a market cap of $2,226.14, a price-to-earnings ratio of 22.74, a PEG ratio of 2.57 and a beta of 1.77. The company has a quick ratio of 1.19, a current ratio of 2.13 and a debt-to-equity ratio of 0.49. Halyard Health has a 12-month low of $35.24 and a 12-month high of $50.99.

Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.13. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The company had revenue of $401.40 million during the quarter, compared to analyst estimates of $394.54 million. During the same quarter last year, the business posted $0.48 EPS. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. equities analysts forecast that Halyard Health will post 2.08 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Halyard Health Inc (HYH) Receives Average Recommendation of “Buy” from Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/15/halyard-health-inc-hyh-receives-average-recommendation-of-buy-from-analysts.html.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.